Ovarian Cancer

Rubraca Granted Accelerated FDA Approval for Advanced BRCA-positive Ovarian Cancer

Rubraca Granted Accelerated FDA Approval for Advanced BRCA-positive Ovarian Cancer

By

Rubraca (rucaparib) received accelerated approval by the U.S. Food and Drug Administration for the treatment of patients with previously treated BRCA-positive ovarian cancer.

Including a PI3-Kinase Inhibitor with an PARP Inhibitor Improves Tumor Shrinkage in Patients with Resistant Ovarian Cancer

Including a PI3-Kinase Inhibitor with an PARP Inhibitor Improves Tumor Shrinkage in Patients with Resistant Ovarian Cancer

By

Tumor shrinkage was seen in plantinum-resistant ovarian tumors when treated with a combination of a PARP inhibitor and an alpha-specific PI3-kinase inhibitor.

Concurrent, Maintenance Therapy With Cediranib Maintains QOL in Ovarian Cancer

Concurrent, Maintenance Therapy With Cediranib Maintains QOL in Ovarian Cancer

By

Quality of life was maintained in patients with ovarian cancer who received chemotherapy with concurrent cediranib then cediranib alone as maintenance therapy.

12 More Genetic Variants Found to Increase Risk for Ovarian Cancer

12 More Genetic Variants Found to Increase Risk for Ovarian Cancer

By

A team of international researchers identified 12 new genetic variants that increase a woman's risk of developing ovarian cancer.

Quarterly Testing for Biomarker Improves Detection of Early-Stage Ovarian Cancer in High-Risk Women

Quarterly Testing for Biomarker Improves Detection of Early-Stage Ovarian Cancer in High-Risk Women

By

A protocol of testing of CA125 levels quarterly with subsequent transvaginal ultrasound examination increased detection of early-stage ovarian cancer in women at high-risk for the disease.

Priority Symptoms Identified in Recurrent Ovarian Cancer

Priority Symptoms Identified in Recurrent Ovarian Cancer

By

There are 18 core priority symptoms that should be routinely assessed in patients with recurrent ovarian cancer to provide higher quality of care.

Web-based Symptom Management Improves Symptom Controllability in Ovarian Cancer

Web-based Symptom Management Improves Symptom Controllability in Ovarian Cancer

By

Nurse-guided and self-directed web-based symptom management interventions (WRITE Symptoms) improved symptom controllability among women with recurrent ovarian cancer.

Some Quality Metrics Inconsistent With Long-Term Clinical Outcomes Goals

Some Quality Metrics Inconsistent With Long-Term Clinical Outcomes Goals

By

Study finds that instituting a health system-wide quality metric, such as postoperative hospital readmission rate, may be inconsistent with long-term clinical outcomes goals.

Ovarian Cancer: Distinct Clusters of Chemotherapy Nonresponders Identified

Ovarian Cancer: Distinct Clusters of Chemotherapy Nonresponders Identified

By

A study that integrated genomic and clinical data identified 3 distinct clusters of patients with serous epithelial ovarian cancer who do not respond to chemotherapy.

Recovery Program After Laparotomy More Cost-Effective Than Usual Care

Recovery Program After Laparotomy More Cost-Effective Than Usual Care

By

An enhanced recovery program is more cost-effective than usual care in patients undergoing primary cytoreductive surgery for ovarian cancer.

Rucaparib Active in Relapsed, Platinum-sensitive Ovarian Cancer

Rucaparib Active in Relapsed, Platinum-sensitive Ovarian Cancer

By

Rucaparib was active with an acceptable safety profile in patients with relapsed, platinum-sensitive high-grade ovarian carcinoma with germline or somatic BRCA mutations.

HMT Improves PFS in Serous Carcinoma of the Ovary, Peritoneum

HMT Improves PFS in Serous Carcinoma of the Ovary, Peritoneum

By

Individuals with serious carcinoma of the ovary or peritoneum experienced improved progression-free survival after hormone maintenance therapy.

Rucaparib Monotherapy Approved for Advanced Ovarian Cancer

Rucaparib Monotherapy Approved for Advanced Ovarian Cancer

By

Rucaparib has been approved for the treatment of patients with advanced ovarian cancer who harbor a deleterious BRCA mutation.

Primary Cytoreductive Surgery Associated With Improved Survival in Ovarian Cancer

Primary Cytoreductive Surgery Associated With Improved Survival in Ovarian Cancer

By

The benefits of primary cytoreductive surgery relative to neoadjuvant chemotherapy remain uncertain; therefore, researchers performed a retrospective data analysis to compare overall survival of surgery with that of neoadjuvant chemotherapy in advanced-stage epithelial ovarian cancer.

Neoadjuvant Chemotherapy Use on the Rise in Ovarian Cancer Treatment

Neoadjuvant Chemotherapy Use on the Rise in Ovarian Cancer Treatment

NeoadjuvantcChemotherapy (NACT) use went up from 2003 to 2012; linked to shorter overall survival in stage IIIC but not stage IV disease.

Chemotherapy During Pregnancy May Limit Baby's Fertility in Girls

Chemotherapy During Pregnancy May Limit Baby's Fertility in Girls

By

Etoposide was found to damage ovarian tissue in the developing fetus in a study evaluating the effect of the drug on mouse ovarian tissue grown in vitro.

Novel Pathway Improves Access to Genetic Testing for Women With Ovarian Cancer

Novel Pathway Improves Access to Genetic Testing for Women With Ovarian Cancer

By

Rapid, robust, and affordable genetic testing for patients with ovarian cancer that allows a much larger portion of patients to benefit from personalized cancer management and their relatives to benefit from preventive strategies can be achieved.

Socioeconomic Status Inversely Related to Risk for Ovarian Cancer in African American Women

By

Risk of ovarian cancer is higher in African American women with lower socioeconomic status, the opposite of trends seen in breast cancer.

Imaging and Fluorescence Technique Guides Surgical Removal of Otherwise Undetectable Ovarian Tumors

By

A newly created tumor-specific fluorescent molecule combined with an imaging system guided surgeons to removing additional tumors not palpable or visible without fluorescence in patients with ovarian cancer.

Chemotherapy Boosts Effectiveness of Immunotherapy in the Treatment of Ovarian Cancer

Chemotherapy Boosts Effectiveness of Immunotherapy in the Treatment of Ovarian Cancer

By

Immunotherapy for advanced ovarian cancer more effectively treats tumors when administered immediately after chemotherapy. Sequential chemoimmunotherapy could improve disease control in stage IIIC/IV tubo-ovarian HGSC.

Exercise May Protect Against Epithelial Ovarian Cancer

Exercise May Protect Against Epithelial Ovarian Cancer

Chronic inactivity has been linked to greater risk for ovarian cancer.

Number of Ovarian Cancer Cases Not Treated Surgically or Not Treated at All Is Increasing

Number of Ovarian Cancer Cases Not Treated Surgically or Not Treated at All Is Increasing

By

The number of patients older than 75 years who do not undergo surgery is increasing, especially among those with stage III or IV ovarian cancer. Approximately 50% do not undergo surgery and 25% receive no treatment at all.

Genetic Subtypes of HLA Are Linked to Increased Overall Risk of Ovarian Cancer

By

Overall risk of developing ovarian cancer may be higher for women with certain types of human leukocyte antigen (HLA), which could underlie differences in their response to immunotherapy.

Cell Changes in Fallopian Tubes of BRCA Mutation Carriers May Lead to Strategies for Preventing Ovarian Cancer

By

Recognition of early changes in the Fallopian tube cells of BRCA gene mutation carriers may be key to new strategies for preventing ovarian cancer that could also reduce the need for invasive surgery.

Study Finds Racial Disparities in Breast and Ovarian Cancer Risk Management

Study Finds Racial Disparities in Breast and Ovarian Cancer Risk Management

By

Disparities in cancer risk management among BRCA carriers across a diverse sample of young black, Hispanic, and non-Hispanic white breast cancer survivors underscores that "the benefit from genetic testing comes from acting on the test results," not just the testing itself, a study presented at the ASCO 2016 Annual Meeting concluded.

T Cells Have the Potential to Reverse Chemotherapy Resistance in Patients With Ovarian Cancer

By

A new perspective on chemotherapy resistance in ovarian cancer may be a step toward overcoming that resistance. Fibroblasts block chemotherapy, leading to chemotherapy resistance; however, immune system T cells can reverse that resistance.

No Clinical Benefit to Expanding Gene Panel Beyond Ovarian and Breast Cancer Genes in High-risk Women

By

Expanding a panel of tested genes beyond the known breast and ovarian cancer-specific genes in patients with breast and ovarian cancer did not confer any clinical benefit.

Obesity Can Mask Ovarian Cancer Symptoms in African American Women

By

Excess abdominal fat in overweight and obese women could interfere with detection of early symptoms of ovarian cancer, and this may contribute to the higher risk of death from ovarian cancer in African American women compared with white women.

Effect of Childbirth on Risk of Ovarian Cancer Diminishes With Age, But Effect of Oral Contraceptive Use Is Constant

Effect of Childbirth on Risk of Ovarian Cancer Diminishes With Age, But Effect of Oral Contraceptive Use Is Constant

By

Prior oral contraceptive use is associated with reduced risk for ovarian cancer among women of all ages; however, risk reductions associated with childbirth wane as women age

Optimal Tumor Reduction, Platinum Sensitivity Characterize Long-term Ovarian Cancer Survival

Optimal Tumor Reduction, Platinum Sensitivity Characterize Long-term Ovarian Cancer Survival

By

Women who are long-term survivors of high-grade serous carcinoma (HGSC) usually have platinum-sensitive disease.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs